Rigel Pharmaceuticals, Inc. , a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Dean Schorno, the company's chief financial officer, will ...

Cellares, the world's first Integrated Development and Manufacturing Organization (IDMO), and a leader in automated cell therapy manufacturing, has appointed Ossama Eissa, former executive at Novartis ...

As a leading CDMO for bioconjugates, Lonza has produced over 1,000 cGMP batches for more than 70 programs since 2006. Lonza offers customers a fully integrated solution, spanning design and lead ...

Emerging from the rough waters of the CDMO industry with a new chief executive at the helm, AGC Biologics is on a mission to reinvent itself as a manufacturing partner defined by friendliness and e | ...

Santagostino, who was announced in the role in late October, joined AGC Biologics from the pharmaceutical manufacturing ...

The Dutch biotech Synaffix and the Swiss company BigHat Biosciences announced yesterday that they have entered into a ...

Lonza has continued to adapt to the evolving ADC landscape, including the recent addition of a highly potent vial fill ...

BigHat Biosciences is adding Synaffix’s antibody-drug conjugate (ADC) tech to its wardrobe, pairing the science with its antibody design platform to tailor a next-gen ADC pipeline. | BigHat ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studiesCollaboration underscores Lonza's commitment to helping customers deliver ...

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies Collaboration underscores ...

The exosome market is fueled by several significant factors, such as the rising incidence of chronic diseases, improvements in diagnostic methods, and heightened interest in personalized medicine.

The global mRNA synthesis and manufacturing market is projected to grow from USD 2,231.4 million in 2024 to USD 2,958.3 ...